佰泽医疗 公布招股结果,确定以4.22港元下限定价,集资净额4.68亿港元。
公开发售接获25.92倍认购,一手(600股)中签率20%,认购9,000股获稳派一手。国际发售录得0.98倍认购。经重新分配,公开发售股份已增加至1,623.84万股,占发售总数12.2%。股份预期今日(23日)上市。
中国肿瘤医疗集团佰泽医疗本次拟全球发售1.33亿股,公开发售原占10%。招股价介乎4.22-6.75元。基石投资者Harvest Oriental认购1,900万美元公司股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.